About the Authors
- Ignacio Garrido-Laguna
-
* E-mail: Ignacio.garrido-laguna@hci.utah.edu
Affiliation Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America
- David S. Hong
-
Affiliation Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America
- Filip Janku
-
Affiliation Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America
- Ly M. Nguyen
-
Affiliation Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America
- Gerald S. Falchook
-
Affiliation Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America
- Siqing Fu
-
Affiliation Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America
- Jenifer J. Wheler
-
Affiliation Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America
- Rajyalakshmi Luthra
-
Affiliation Department of Molecular Diagnostic Laboratory, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America
- Aung Naing
-
Affiliation Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America
- Xuemei Wang
-
Affiliation Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America
- Razelle Kurzrock
-
Affiliation Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America
Competing Interests
The authors have declared that no competing interests exist.
Author Contributions
Conceived and designed the experiments: IGL DSH FJ XW RK. Performed the experiments: IGL RL. Analyzed the data: IGL DSH FJ XW RK. Contributed reagents/materials/analysis tools: IGL DSH FJ LMN GSF SF JJW RL AN XW RK. Wrote the paper: IGL DSH FJ XW RK.